Far EasTone Telecommunications Co Ltd (遠傳電信) yesterday said it plans to set up an indoor 5G trial field next month at Neihu Technology Park (內湖科技園區) for 100 enterprises or research organizations to run three-month free trials, a day after the telecom won the first approval to install a 5G-based Proof of Business network.
The telecom said it plans to offer the trials in collaboration with Ericsson Taiwan (台灣愛立信) at the Neihu Sports Center on a commercial 5G network using the 3.5 gigahertz band.
As part of the trials, the telecom is to supply free 5G SIM cards, routers and an application enablement platform, allowing firms to utilize it to test Internet of Things (IoT) business opportunities from this month to December.
Photo: CNA
The average download speed of the 5G network is at least 10 times faster than a 4G LTE network, the company said.
“We hope the trials help upstream and downstream companies transit to 5G technology more smoothly,” Far EasTone vice president Philip Tseng (曾詩淵) told reporters on the sidelines of a news conference in Taipei.
The telecom is teaming up with Taipei’s Smart City Project Management Office, Department of Information Technology and Department of Economic Development, as well as the Taiwan IOT Technology and Industry Association (台灣物聯網產業技術協會) to launch the 5G trials.
Notebook computer maker Compal Electronics Inc (仁寶電腦) and smartphone maker HTC Corp (宏達電) are to provide the testing ground, the telecom said.
The announcement came after the National Communications Commission on Thursday approved Far EasTone’s plan to deploy a 5G proof-of-business network.
The commission has approved six 5G proof-of-concept trials and is still reviewing other applications, it said, adding that it welcomes more applications to explore business opportunities or business models on 5G networks.
Telecoms that win 5G spectrum licenses are expected to launch commercial 5G services in July next year at the earliest, the commission said.
UNCONVINCING: The US Congress questioned whether the company’s Chinese owners pose a national security risk and how the app might influence young users TikTok chief executive officer Shou Chew (周受資), confronted with an unforgiving, distrustful US Congress, tried to give answers in his testimony on Thursday that avoided offending either the US government or China. However, his evasiveness left Congress unsatisfied, with representatives hungrier than ever to punish TikTok for ties to its parent company ByteDance Ltd (字節跳動), based in Beijing. He did not bring his company any closer to a resolution. Politically, TikTok is in a tougher spot. Its executives had been discussing divesting from ByteDance to resolve US national security concerns, people familiar with the matter told Bloomberg. However, China this week said
Microsoft Corp has threatened to cut off access to its Internet search data, which it licenses to rival search engines, if they do not stop using it as the basis for their own artificial intelligence (AI) chat products, people familiar with the dispute have said. The software maker licenses the data in its Bing search index — a map of the Internet that can be quickly scanned in real time — to other companies that offer Web search, such as Apollo Global Management Inc’s Yahoo and DuckDuckGo. Last month, Microsoft integrated a cousin of ChatGPT, OpenAI’s AI-powered chat technology, into Bing. Rivals
The Investment Commission yesterday approved a Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) application to invest an additional US$3.5 billion in its Arizona subsidiary to manufactured advanced chips. The world’s largest contract chipmaker’s board of directors last month approved the funding project after TSMC started moving manufacturing equipment into the fab in December last year in preparation for the production of 4-nanometer chips next year. TSMC said it has also commenced the second phase of facility construction in Arizona. The second fab is to produce semiconductors using 3-nanometer technology in 2026. Altogether, TSMC plans to spend US$40 billion on the Arizona fabs, doubling its
Sanofi SA’s drug Dupixent succeeded in a late-stage trial for chronic obstructive pulmonary disease (COPD), raising the odds that the blockbuster would be the first biologic medicine cleared to treat the lung disorder. Dupixent, which is already prescribed for asthma and some skin conditions, showed a 30 percent reduction in the rate at which patients’ COPD worsened compared with those who received a placebo during the stage-three Boreas trial, the company said in a statement yesterday. The positive data could herald a new era of cutting-edge treatments for the life-threatening respiratory affliction and provide another major boost in demand for the French
RSS